New CDC Vital Signs report: Few people diagnosed with hepatitis C receive timely treatment

A new CDC Vital Signs report finds that too few people diagnosed with hepatitis C are being treated, despite availability of medications capable of curing this viral infection. According to CDC's estimates:

  • Overall, less than 1 in 3 people with health insurance get direct-acting antiviral (DAA) treatment for hepatitis C within a year of diagnosis.
  • Treatment is lowest among patients in state-administered Medicaid plans, with less than 1 in 4 Medicaid recipients (23%) being treated within a year of diagnosis.
    • Additionally, Medicaid recipients in states that restrict access to hepatitis C treatment are 23% less likely to receive treatment than Medicaid recipients in states without restrictions.

Hepatitis C is curable with well-tolerated, oral medication. Untreated, hepatitis C can cause liver disease, liver cancer, and death. Treatment prevents illness and death, stops spread of hepatitis C, and is cost-saving. In 2019, hepatitis C contributed to the deaths of more than 14,000 people in the United States.

  • For the past several years, CDC's annual hepatitis C data have shown the highest rates of new infection among adults under 40, indicating that treating this group is critical. However, this new analysis found adults under 40 have the lowest treatment rates by age group.
    • Among those under age 40, hepatitis C is most commonly spread through injection drug use.

Everyone with hepatitis C should have access to lifesaving treatment, regardless of race, ethnicity, age or insurance status. What these data tell us is that at best, only one in three people are treated within a year of being diagnosed and we must reduce the barriers and get more people treated for hepatitis C in our country. This is critical to stop preventable deaths and prevent new infections."

Dr. Debra Houry, M.D., M.P.H., CDC Acting Principal Deputy Director

To ensure people diagnosed with hepatitis C are treated, healthcare providers, insurers, policy makers, and public health professionals should:

  • Remove eligibility restrictions and preauthorization requirements that make it difficult for people with hepatitis C to access treatment that will cure the infection.
  • Provide treatment where people already receive services, such as primary care offices, community clinics, syringe services programs, substance use treatment centers, and correctional facilities.
  • Provide treatment in as few visits as possible.
  • Expand the number of primary care providers treating hepatitis C.

People shouldn't have to jump over hurdles to access lifesaving, cost-effective treatment. Removing barriers to treatment is a critical step, as is increasing screening for hepatitis C. We estimate about 40% of people with hepatitis C in the U.S. are unaware of their infection-;testing is the first step to accessing curative treatment."

Carolyn Wester, M.D., M.P.H., director of CDC's Division of Viral Hepatitis

CDC recommends that everyone get tested for hepatitis C at least once in their lifetime and that people with ongoing risk factors for hepatitis C receive routine periodic testing.

  • To find free hepatitis C testing in their area, people can visit
  • People diagnosed with hepatitis C should talk to a provider to start treatment and get cured.
  • Those without insurance or who cannot afford treatment can explore pharmaceutical patient assistance programs and cost-sharing assistance programs.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study explores the intricate gut-brain-liver connection and its impact on health